1
|
Sidaway P. Durable responses to belzutifan in patients with VHL disease. Nat Rev Clin Oncol 2025; 22:382. [PMID: 40281323 DOI: 10.1038/s41571-025-01023-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2025]
|
2
|
Ciccarese C, Iacovelli R, Tortora G. Belzutifan in von Hippel-Lindau disease. Lancet Oncol 2025; 26:531-533. [PMID: 40228515 DOI: 10.1016/s1470-2045(25)00153-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2025] [Revised: 03/12/2025] [Accepted: 03/12/2025] [Indexed: 04/16/2025]
Affiliation(s)
- Chiara Ciccarese
- Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Roberto Iacovelli
- Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Giampaolo Tortora
- Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy; Medical Oncology, Università Cattolica del Sacro Cuore, Rome, Italy.
| |
Collapse
|